EcoDrugPlus

Cathepsin S, Ortholog2, Tandem Duplicate 1

Ensembl ID : ENSOJAG00000006067
Gene Symbol: CTSS2.1
1 Cross references
233 Possible Orthologues:

Cell Division Cycle 7 Homolog (S. Cerevisiae)

Ensembl ID : ENSOJAG00000012454
Gene Symbol: CDC7
1 Cross references
207 Possible Orthologues:

Checkpoint Kinase 2

Ensembl ID : ENSOJAG00000007495
Gene Symbol: CHEK2
1 Cross references
205 Possible Orthologues:

Chemokine (C-C Motif) Receptor 9a

Ensembl ID : ENSOJAG00000018803
Gene Symbol: CCR9A
1 Cross references
188 Possible Orthologues:

Chemokine (C-X-C Motif) Receptor 4a

Ensembl ID : ENSOJAG00000023451
Gene Symbol: CXCR4A
1 Cross references
201 Possible Orthologues:

Cholecystokinin A Receptor

Ensembl ID : ENSOJAG00000010271
Gene Symbol: CCKAR
1 Cross references
200 Possible Orthologues:

Cholecystokinin B Receptor A

Ensembl ID : ENSOJAG00000000465
Gene Symbol: CCKBRA
1 Cross references
193 Possible Orthologues:

Cholesteryl Ester Transfer Protein, Plasma

Ensembl ID : ENSOJAG00000012255
Gene Symbol: CETP
1 Cross references
137 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSOJAG00000019981
Gene Symbol: CHRM3
1 Cross references
187 Possible Orthologues:

Cholinergic Receptor Muscarinic 3

Ensembl ID : ENSOJAG00000019337
Gene Symbol: CHRM3
1 Cross references
186 Possible Orthologues:

Cholinergic Receptor Muscarinic 4

Ensembl ID : ENSOJAG00000018412
Gene Symbol: CHRM4
1 Cross references
184 Possible Orthologues:

Cholinergic Receptor Nicotinic Alpha 3 Subunit

Ensembl ID : ENSOJAG00000019938
Gene Symbol: CHRNA3
1 Cross references
202 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).